糖尿病患者血脂管理中国专家共识(2024版)

2024-04-24 中国循环杂志 发表于上海

本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

中文标题:

糖尿病患者血脂管理中国专家共识(2024版)

发布机构:

发布日期:

2024-04-24

简要介绍:

糖尿病是动脉粥样硬化性心血管疾病(ASCVD)的重要独立危险因素,血脂异常在糖尿病患者的ASCVD发生和发展中起关键作用。目前我国糖尿病患者中血脂异常患病率高且控制现状不容乐观。因此,为了加强糖尿病患者的血脂管理,中国医师协会内分泌代谢科医师分会和国家心血管病专家委员会心血管代谢医学专业委员会组织专家,根据中国糖尿病患者的血脂管理现状,参考国内外新的循证证据和指南,制定了《糖尿病患者血脂管理中国专家共识(2024版)》。本共识内容涵盖糖尿病患者的血脂谱特点和血脂异常流行病学现状以及糖尿病全人群的ASCVD危险分层和血脂管理流程,首次将低密度脂蛋白胆固醇(LDL-C)与非高密度脂蛋白胆固醇(非HDL-C)均作为糖尿病患者血脂干预的首要靶点,并对糖尿病特殊人群(包括儿童和青少年、≥75岁老年人以及合并慢性肾脏病、代谢相关脂肪性肝病、妊娠的患者)的血脂管理策略进行了推荐。本共识旨在传递重要临床进展,指导临床实践,以改善糖尿病患者的心血管结局。

相关资料下载:
糖尿病患者血脂管理中国专家共识(2024版).pdf
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-11 田沛文 来自山西省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 坐井观天下 来自海南省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 ms5000000231838559 来自湖北省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2204104, encodeId=44592204104b3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6gIknBJqfuPhRvIvBCic3jbz4PVDcMREDl6iaWw7opPo99JEXWc0tmIrGaXGPP0y58DKDiajZfV2qR3qXdCgwIyhVq/0, createdBy=d71a1955931, createdName=田沛文, createdTime=Sat May 11 15:58:12 CST 2024, time=2024-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2203709, encodeId=1c482203e0927, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220801/c298eeb2259c4110b14179b97aba2e82/436f77ef216745e49f4d7dbc87ea096e.jpg, createdBy=15fd6475276, createdName=坐井观天下, createdTime=Thu May 09 16:18:14 CST 2024, time=2024-05-09, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2203674, encodeId=894e22036e402, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f09271847, createdName=ms5000000231838559, createdTime=Thu May 09 14:38:00 CST 2024, time=2024-05-09, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203671, encodeId=de9622036e1d4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1802200015, createdName=慢川, createdTime=Thu May 09 14:31:08 CST 2024, time=2024-05-09, status=1, ipAttribution=浙江省)]
    2024-05-09 慢川 来自浙江省

    学习了

    0

拓展阅读

中国超35%人血脂异常!2024指南:每半年一次降脂药将“坏胆固醇”降低60%……

近年来,中国成人血脂异常患病率一直处于较高水平,2018年调查数据显示其总患病率达到了35.6%,与2015年调查数据相比有所上升。在此背景下,血脂管理刻不容缓。

CGP指南 | 血脂管理最新更新要点——基于中国血脂管理指南(基层版2024年)

为便于基层医生更好地开展血脂管理,中国血脂管理指南修订联合专家委员会在《中国血脂管理指南(2023年)》基础上,制定了《中国血脂管理指南(基层版2024年)》,重点更新内容如下。

CGP指南|中国血脂管理指南(基层版2024年)

本指南旨在为基层医生开展血脂管理提供指导,全面提升基层医生的血脂管理水平,推进ASCVD的一级和二级预防工作。

Lower for Longer!血脂管理迈向“更早、更长、更稳”

我国的血脂管理指南继2016年后再次得到一次更新改版,旨在在新的卫生健康形势下,结合新的医疗进展,进一步规范我国的血脂管理,指导临床实践,全面提升我国血脂管理水平,推进动脉粥样硬化性心血管疾病防治。

“坏胆固醇”降低近90%!2024年中国血脂指南强调2大有效策略

《社区成人血脂异常管理中国专家共识(2024年)》参考中国及国际相关成人血脂管理指南及最新的循证医学证据,从临床实践角度出发,旨在加强中国成人血脂异常的管理,并在更广泛人群中进行ASCVD防控。

OCC 2022:刘静教授——血脂管理,多早算早?

LDL-C是血脂管理的首要目标,各个指南都推荐早进行血脂监测和管理,到底多早才算早呢?

2015 ACC/AHA 二级预防血脂管理绩效评估指南

美国心脏病学会(ACC,American College of Cardiology) · 2015-12-10

2020 TES临床实践指南:内分泌疾病患者的血脂管理

美国内分泌学会(TES,The Endocrine Society) · 2020-12-01

2022 中国台湾指南:高风险患者的血脂管理—冠状动脉疾病、外周动脉疾病和缺血性卒中(更新版)

中国台湾血脂及动脉硬化学会(Taiwan Society of Lipids & Atherosclerosis) · 2022-04-08

2019年ESC/EAS血脂管理指南要点解读

中国医学科学院北京协和医学院国家心血管病中心阜外医院血脂异常与心血管疾病诊治中心 · 2019-11-20

2020 AACE临床实践指南:内分泌疾病患者的血脂管理

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2020-05-13